Drab A, Wdowiak K, Kanadys W, Zajaczkowski K, Koczkodaj P, Religioni U
Cancers (Basel). 2024; 16(23).
PMID: 39682196
PMC: 11640538.
DOI: 10.3390/cancers16234010.
Yamashiro K, Takahashi H, Hayashino Y, Origasa H, Izumi K, Tajima N
Diabetol Int. 2024; 15(3):315-326.
PMID: 39101169
PMC: 11291822.
DOI: 10.1007/s13340-024-00725-6.
Ye G, Yang Y, Luo K, Wang S, Xia Q
Aging (Albany NY). 2024; 16(11):9584-9598.
PMID: 38836754
PMC: 11210264.
DOI: 10.18632/aging.205886.
Welen K, Damber J
Rev Endocr Metab Disord. 2022; 23(6):1221-1231.
PMID: 35748976
PMC: 9789017.
DOI: 10.1007/s11154-022-09730-z.
Palomar-Cros A, Espinosa A, Straif K, Perez-Gomez B, Papantoniou K, Gomez-Acebo I
Nutrients. 2021; 13(8).
PMID: 34444822
PMC: 8399976.
DOI: 10.3390/nu13082662.
Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
Amadou A, Freisling H, Jenab M, Tsilidis K, Trichopoulou A, Boffetta P
Br J Cancer. 2021; 124(11):1882-1890.
PMID: 33772152
PMC: 8144608.
DOI: 10.1038/s41416-021-01347-4.
Type 2 Diabetes and Cancer: An Umbrella Review of Observational and Mendelian Randomization Studies.
Pearson-Stuttard J, Papadimitriou N, Markozannes G, Cividini S, Kakourou A, Gill D
Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1218-1228.
PMID: 33737302
PMC: 9398112.
DOI: 10.1158/1055-9965.EPI-20-1245.
The association of diabetes with risk of prostate cancer defined by clinical and molecular features.
Feng X, Song M, Preston M, Ma W, Hu Y, Pernar C
Br J Cancer. 2020; 123(4):657-665.
PMID: 32467600
PMC: 7435261.
DOI: 10.1038/s41416-020-0910-y.
Prospective study of cancer in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.
Iwase M, Fujii H, Idewaki Y, Nakamura U, Ohkuma T, Ide H
Diabetol Int. 2019; 10(4):260-267.
PMID: 31592402
PMC: 6763543.
DOI: 10.1007/s13340-019-00390-0.
Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific....
Kobayashi M, Mizuno T, Yuki H, Kambara T, Betsunoh H, Nukui A
Int J Clin Oncol. 2019; 25(3):472-478.
PMID: 31440861
DOI: 10.1007/s10147-019-01527-6.
Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship.
Di Francesco S, Robuffo I, Caruso M, Giambuzzi G, Ferri D, Militello A
Medicina (Kaunas). 2019; 55(3).
PMID: 30866568
PMC: 6473682.
DOI: 10.3390/medicina55030062.
Malignancy incidences by glycemic control among diabetic patients.
Kobayashi D, Kuriyama N, Hirano K, Takahashi O, Noto H
Endocr Connect. 2018; 7(12):1457-1463.
PMID: 30508417
PMC: 6300859.
DOI: 10.1530/EC-18-0355.
Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis.
Yao W, Meng Y, Lu M, Fan W, Huang J, Li J
Cancer Commun (Lond). 2018; 38(1):14.
PMID: 29764483
PMC: 5993151.
DOI: 10.1186/s40880-018-0275-2.
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.
Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L
Ecancermedicalscience. 2018; 12:802.
PMID: 29456619
PMC: 5813911.
DOI: 10.3332/ecancer.2018.802.
Association between diabetes mellitus and subsequent ovarian cancer in women: A systematic review and meta-analysis of cohort studies.
Wang L, Wang L, Zhang J, Wang B, Liu H
Medicine (Baltimore). 2017; 96(16):e6396.
PMID: 28422831
PMC: 5406047.
DOI: 10.1097/MD.0000000000006396.
The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.
Xu H, Fu S, Chen Q, Gu M, Zhou J, Liu C
Oncotarget. 2017; 8(19):31215-31226.
PMID: 28415720
PMC: 5458202.
DOI: 10.18632/oncotarget.16107.
The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.
Khan S, Cai J, Nielsen M, Troester M, Mohler J, Fontham E
Cancer Causes Control. 2016; 27(12):1475-1485.
PMID: 27830399
PMC: 5139913.
DOI: 10.1007/s10552-016-0828-0.
Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Haggstrom C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L
Int J Cancer. 2016; 140(3):611-617.
PMID: 27770555
PMC: 5215657.
DOI: 10.1002/ijc.30480.
Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.
Raval A, Mattes M, Madhavan S, Pan X, Wei W, Sambamoorthi U
J Diabetes Res. 2016; 2016:2656814.
PMID: 27547763
PMC: 4983375.
DOI: 10.1155/2016/2656814.
Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men.
Dankner R, Boffetta P, Keinan-Boker L, Balicer R, Berlin A, Olmer L
Diabetologia. 2016; 59(8):1683-91.
PMID: 27189066
PMC: 4930460.
DOI: 10.1007/s00125-016-3972-x.